PL1931335T3 - Modulatory heksahydrocyklooktylopirazolokannabinoidowe - Google Patents
Modulatory heksahydrocyklooktylopirazolokannabinoidoweInfo
- Publication number
- PL1931335T3 PL1931335T3 PL06804133T PL06804133T PL1931335T3 PL 1931335 T3 PL1931335 T3 PL 1931335T3 PL 06804133 T PL06804133 T PL 06804133T PL 06804133 T PL06804133 T PL 06804133T PL 1931335 T3 PL1931335 T3 PL 1931335T3
- Authority
- PL
- Poland
- Prior art keywords
- hexahydro
- cyclooctyl
- cannabinoid modulators
- pyrazole cannabinoid
- cyclooctyl pyrazole
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 2
- 239000003557 cannabinoid Substances 0.000 title abstract 2
- NNRSEKSIYNJCLU-UHFFFAOYSA-N 5-cyclooctyl-1h-pyrazole Chemical compound C1CCCCCCC1C1=NNC=C1 NNRSEKSIYNJCLU-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71988405P | 2005-09-23 | 2005-09-23 | |
| PCT/US2006/037350 WO2007044215A1 (en) | 2005-09-23 | 2006-09-22 | Hexahydro cyclooctyl pyrazole cannabinoid modulators |
| EP06804133A EP1931335B1 (en) | 2005-09-23 | 2006-09-22 | Hexahydro cyclooctyl pyrazole cannabinoid modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1931335T3 true PL1931335T3 (pl) | 2010-07-30 |
Family
ID=37651059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06804133T PL1931335T3 (pl) | 2005-09-23 | 2006-09-22 | Modulatory heksahydrocyklooktylopirazolokannabinoidowe |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7851498B2 (pl) |
| EP (1) | EP1931335B1 (pl) |
| JP (1) | JP5162461B2 (pl) |
| KR (1) | KR20080066924A (pl) |
| CN (1) | CN101312725B (pl) |
| AT (1) | ATE458480T1 (pl) |
| AU (1) | AU2006302659A1 (pl) |
| BR (1) | BRPI0616401A2 (pl) |
| CA (1) | CA2623535A1 (pl) |
| CY (1) | CY1110020T1 (pl) |
| DE (1) | DE602006012514D1 (pl) |
| DK (1) | DK1931335T3 (pl) |
| EA (1) | EA200800889A1 (pl) |
| EC (1) | ECSP088315A (pl) |
| ES (1) | ES2340201T3 (pl) |
| HR (1) | HRP20100258T1 (pl) |
| IL (1) | IL190348A0 (pl) |
| MY (1) | MY148863A (pl) |
| NO (1) | NO20081950L (pl) |
| NZ (1) | NZ567006A (pl) |
| PL (1) | PL1931335T3 (pl) |
| PT (1) | PT1931335E (pl) |
| RS (1) | RS51298B (pl) |
| SI (1) | SI1931335T1 (pl) |
| UA (1) | UA93389C2 (pl) |
| WO (1) | WO2007044215A1 (pl) |
| ZA (1) | ZA200803533B (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| WO2008115672A1 (en) * | 2007-03-21 | 2008-09-25 | Janssen Pharmaceutica N.V. | Method for treating cb2 receptor mediated pain |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| HUE043555T2 (hu) | 2007-11-30 | 2019-09-30 | Zynerba Pharmaceuticals Inc | Tetrahidrokannabinol gyógyszer elõanyagai (prodrugjai), kompozíciók, amelyek tetrahidrokannabinol gyógyszer elõanyagait tartalmazzák, és eljárások, ezek alkalmazására |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2948718A (en) * | 1960-08-09 | New n-heterocyclic compounds | ||
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| CS234018B2 (en) * | 1979-06-01 | 1985-03-14 | Wellcome Found | Method of 3,5-diammino-6-1,2,4-triazine derivatives making |
| LU83729A1 (fr) * | 1981-11-04 | 1983-09-01 | Galephar | Sels d'acide valproique,leur preparation et leur utilisation |
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
| FR2800375B1 (fr) * | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| EP1698335A4 (en) * | 2003-12-26 | 2007-08-01 | Ono Pharmaceutical Co | AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR |
| EP1735286B1 (en) * | 2004-03-24 | 2012-01-04 | Janssen Pharmaceutica NV | Tetrahydro-indazole cannabinoid modulators |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| KR20070074638A (ko) * | 2004-10-27 | 2007-07-12 | 얀센 파마슈티카 엔.브이. | 테트라하이드로 피리디닐 피라졸 카나비노이드 모듈레이터 |
-
2006
- 2006-09-22 RS RSP-2010/0185A patent/RS51298B/sr unknown
- 2006-09-22 AU AU2006302659A patent/AU2006302659A1/en not_active Abandoned
- 2006-09-22 US US11/525,573 patent/US7851498B2/en not_active Expired - Fee Related
- 2006-09-22 PL PL06804133T patent/PL1931335T3/pl unknown
- 2006-09-22 KR KR1020087009596A patent/KR20080066924A/ko not_active Application Discontinuation
- 2006-09-22 JP JP2008532489A patent/JP5162461B2/ja not_active Expired - Fee Related
- 2006-09-22 WO PCT/US2006/037350 patent/WO2007044215A1/en active Application Filing
- 2006-09-22 AT AT06804133T patent/ATE458480T1/de active
- 2006-09-22 CN CN200680043512XA patent/CN101312725B/zh not_active Expired - Fee Related
- 2006-09-22 DK DK06804133.4T patent/DK1931335T3/da active
- 2006-09-22 UA UAA200803833A patent/UA93389C2/ru unknown
- 2006-09-22 DE DE602006012514T patent/DE602006012514D1/de active Active
- 2006-09-22 NZ NZ567006A patent/NZ567006A/en not_active IP Right Cessation
- 2006-09-22 BR BRPI0616401-3A patent/BRPI0616401A2/pt not_active IP Right Cessation
- 2006-09-22 CA CA002623535A patent/CA2623535A1/en not_active Abandoned
- 2006-09-22 ES ES06804133T patent/ES2340201T3/es active Active
- 2006-09-22 PT PT06804133T patent/PT1931335E/pt unknown
- 2006-09-22 SI SI200630638T patent/SI1931335T1/sl unknown
- 2006-09-22 MY MYPI20080784A patent/MY148863A/en unknown
- 2006-09-22 EA EA200800889A patent/EA200800889A1/ru unknown
- 2006-09-22 EP EP06804133A patent/EP1931335B1/en active Active
-
2008
- 2008-03-20 IL IL190348A patent/IL190348A0/en unknown
- 2008-03-26 EC EC2008008315A patent/ECSP088315A/es unknown
- 2008-04-22 ZA ZA200803533A patent/ZA200803533B/xx unknown
- 2008-04-23 NO NO20081950A patent/NO20081950L/no not_active Application Discontinuation
-
2010
- 2010-05-07 CY CY20101100396T patent/CY1110020T1/el unknown
- 2010-05-10 HR HR20100258T patent/HRP20100258T1/hr unknown
- 2010-05-24 US US12/785,625 patent/US8101592B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MY148863A (en) | 2013-06-14 |
| WO2007044215A1 (en) | 2007-04-19 |
| NZ567006A (en) | 2010-11-26 |
| DE602006012514D1 (de) | 2010-04-08 |
| PT1931335E (pt) | 2010-03-23 |
| EA200800889A1 (ru) | 2008-12-30 |
| US7851498B2 (en) | 2010-12-14 |
| US20100234331A1 (en) | 2010-09-16 |
| ATE458480T1 (de) | 2010-03-15 |
| KR20080066924A (ko) | 2008-07-17 |
| ES2340201T3 (es) | 2010-05-31 |
| CN101312725B (zh) | 2012-01-11 |
| SI1931335T1 (sl) | 2010-06-30 |
| DK1931335T3 (da) | 2010-06-07 |
| ECSP088315A (es) | 2008-04-28 |
| RS51298B (sr) | 2010-12-31 |
| NO20081950L (no) | 2008-05-16 |
| ZA200803533B (en) | 2009-10-28 |
| US20070129417A1 (en) | 2007-06-07 |
| BRPI0616401A2 (pt) | 2011-06-21 |
| US8101592B2 (en) | 2012-01-24 |
| UA93389C2 (en) | 2011-02-10 |
| JP5162461B2 (ja) | 2013-03-13 |
| IL190348A0 (en) | 2009-09-22 |
| EP1931335A1 (en) | 2008-06-18 |
| JP2009509973A (ja) | 2009-03-12 |
| HRP20100258T1 (hr) | 2010-06-30 |
| EP1931335B1 (en) | 2010-02-24 |
| CY1110020T1 (el) | 2015-01-14 |
| CN101312725A (zh) | 2008-11-26 |
| AU2006302659A1 (en) | 2007-04-19 |
| CA2623535A1 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190348A0 (en) | Hexahydro cyclooctyl pyrazole cannabinoid modulators | |
| TW200602324A (en) | Tetrahydro-indazole cannabinoid modulators cross reference to related applications | |
| BRPI0517378A (pt) | moduladores de tetraidro piridinil pirazol canabinóide | |
| IL193479A0 (en) | Modulators of muscarinic receptors | |
| MX2010001714A (es) | Moduladores de canabinoides 5-vinilfenil-1-fenil-pirazol sustituidos. | |
| WO2007112399A3 (en) | Tetrahydro-pyrazolo[3,4-c]pyridine cannabinoid modulators | |
| ECSP088316A (es) | Moduladores sustituidos de 3-amido-tetrahidro-indazolil cannabinoide | |
| NO20082505L (no) | Substtuert 5-heteroaryl-1-fenyl-pyrazol-cannabinoid-modulatorer | |
| UA98487C2 (en) | Hexahydro-cycloheptapyrazole cannabinoid modulators | |
| ZA200803532B (en) | Hexahydro-cycloheptapyrazole cannabinoid modulators | |
| MX2009010159A (es) | Moduladores de cannabinoides hexahidro-ciclooctil pirazol. | |
| ZA200709342B (en) | Tertrahydrothiopyrano pyrazole cannabinoid modulators | |
| UY30972A1 (es) | Moduladores cannabinoides hexahidro-ciclooctilpirazol | |
| UY30971A1 (es) | Moduladores cannabinoides hexahidro-cicloheptapirazol |